The GOAL study: designed to favor a long-acting beta2-agonist?

American journal of respiratory and critical care medicine

Volumn 171, Issue 9, 2005, Pages

  Currie, Graeme P ^a   Lee, Daniel K C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; FLUTICASONE; SALBUTAMOL; SALMETEROL;

ASTHMA; BRONCHUS HYPERREACTIVITY; DRUG COMBINATION; HUMAN; INFLAMMATION; METHODOLOGY; NOTE; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMATION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 20644458756     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.171.9.951     Document Type: Note

References (0)